Donor cell engraftment
| Group . | n . | H-2Dd (%) . |
|---|---|---|
| Vehicle | 5 | 94.7 ± 1.4 |
| WHI-P131 | 3 | 94.5 ± 2.3 |
| MTX | 3 | 97.6 ± 1.0 |
| WHI-P131 + MTX | 7 | 97.0 ± 2.0 |
| Syngeneic controls | 3 | 0.0 ± 0.0 |
| Group . | n . | H-2Dd (%) . |
|---|---|---|
| Vehicle | 5 | 94.7 ± 1.4 |
| WHI-P131 | 3 | 94.5 ± 2.3 |
| MTX | 3 | 97.6 ± 1.0 |
| WHI-P131 + MTX | 7 | 97.0 ± 2.0 |
| Syngeneic controls | 3 | 0.0 ± 0.0 |
Vehicle-treated mice were analyzed at the time of death between 50 and 77 days. All other mice were electively killed and analyzed at the end of the 85-day observation period. Data are presented as mean ± SEM values for the percentage of H-2Dd-positive donor cells in the nucleated peripheral blood cell population.